Ainring (DE)
{name}
{subtitle}
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~51 mi. (Rosenheim, Germany, +144 more cities)
facility
GSK Investigational Site
condition
Endometrial Carcinoma
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~75 mi. (Wels, Austria, +201 more cities)
facility
Klinikum Wels-Grieskirchen GmbH /ID# 221386
condition
Myelodysplastic Syndromes
drug
azacitidine, +1 more drug
drug type
chemotherapy
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~75 mi. (Wels, Austria, +197 more cities)
facility
Klinikum Wels-Grieskirchen GmbH /ID# 239195
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
condition
Acute Myeloid Leukemia
drug
azacitidine, +1 more drug
drug type
chemotherapy
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
~75 mi. (Wels, Austria, +165 more cities)
facility
Klinikum Wels-Grieskirchen GmbH /ID# 220901
biomarker
del(11)(q10), +27 more biomarkers
condition
Myelofibrosis
drug
navitoclax, +1 more drug
drug type
targeted therapy
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~88 mi. (München, Germany, +192 more cities)
facility
Klinikum der Universität München Großhadern, +1 more facility
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~88 mi. (München, Germany, +226 more cities)
facility
Klinikum Rechts der Isar ( Site 0300)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~88 mi. (München, Germany, +147 more cities)
facility
Klinikum der Universitaet in Muenchen ( Site 0446), +1 more facility
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~88 mi. (München, Germany, +199 more cities)
facility
Klinikum rechts der Isar der Technischen Universitaet ( Site 0470)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~88 mi. (München, Germany, +207 more cities)
facility
Klinikum der Universitaet Muenchen - Grosshadern ( Site 1000)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types